闭合复位髓内钉内固定治疗复杂股骨干粉碎骨折

目的探讨闭合复位髓内钉内固定治疗复杂股骨干粉碎骨折（32-C型）的疗效。方法自2005年4月至2009年6月我院收治的股骨干多段粉碎性骨折病例中16例采用了闭合复位髓内钉内固定治疗。根据AO分型,C1型7例,C2型3例,C3型6例。采用自股骨大粗隆顺行插入髓内钉固定13例,自膝关节逆行插入髓内钉固定3例。结果 16例病例均获随访,随访时间10～36个月,平均随访23个月,骨折均愈合,平均愈合时间5个月。膝关节功能按照Kolment标准,优14例,良2例,优良率100%。结论对于复杂股骨干粉碎骨折采用闭合复位髓内钉内固定具有创伤小,骨折愈合好,患者恢复快的优点。     

带锁髓内钉内固定治疗股骨干粉碎性骨折

目的：报告带锁髓内钉内固定治疗股骨干粉碎性骨折的临床效果。方法：本组12例。男9例，女3例。年龄20-72岁，均为闭合性粉碎性骨折，根据健侧股骨X线片测量选择髓内钉型号，采用闭合或小切口的方法将骨折复位和置入主钉，安装瞄准器后置入上下端锁钉，全部静力固定，对骨折碎片应尽量保护血运和力求靠拔，不苛求完全复位。结果：全部病例获得随访，随访时间10-24个月。全部骨折骨性愈合，平均愈合时间6.5个月。无断钉，松动和感染发生。结论：本方法治疗股骨干粉碎性骨折稳定可靠，骨折愈合快，组织损伤小，允许早期功能锻炼，可避免骨折内固定手术后的诸多并发症，临床效果好。     

闭合复位带锁髓内钉治疗股骨干骨折

目的：探讨闭合复位带锁髓内钉治疗股骨干骨折的临床疗效.方法：自2006年3月至2011年12月采用闭合复位带锁髓内钉治疗103例股骨干骨折患者,其中男76例,女27例;年龄19～55岁,平均36岁.按照AO分型：A型64例,B型27例,C型12例;开放性骨折13例（Gustilo Ⅰ型5例,Ⅱ型8例）.观察术后患者骨折愈合时间,并采用膝关节HSS评分标准对术后1年膝关节功能恢复情况进行评价.结果：术中发生股骨颈骨折1例,股骨近端骨折1例,均于术中更换重建钉固定,术后骨折愈合.术中发生腓总神经损伤1例,营养神经治疗4个月后恢复.103例患者全部获得随访,时间12～28个月,平均22个月.全部患者获得骨性愈合,愈合时间3～9个月,平均5个月.髋关节功能全部恢复正常,术后1年膝关节行HSS评分平均90.89±5.06.结论：注重手术操作,力求闭合复位,减少并发症,带锁髓内钉是治疗股骨干骨折的首选方法.     

闭合复位交锁髓内钉固定治疗股骨干骨折

目的探讨闭合复位交锁髓内钉固定治疗股骨干骨折的临床疗效。方法对16例股骨干骨折患者采用闭合复位交锁髓内钉固定。结果 16例均获得随访,时间4~18个月,骨折均愈合。无感染、内固定断裂、脂肪栓塞等发生。疗效按Tohner-Wrnch标准评定:优13例,良3例。结论闭合复位交锁髓内钉固定治疗股骨干骨折创伤小,失血少,手术时间短,骨折愈合快,功能恢复快,疗效满意。     

顺行扩髓交锁髓内钉治疗股骨干骨折(附237例报告)

目的：探讨顺行扩髓交锁髓内钉治疗股骨干骨折的治疗效果。方法：对1996年6月～2002年7月应用顺行扩髓交锁髓内钉治疗237例股骨干骨折进行回顾分析。骨折类型根据AO／ASIF分类，A型骨折88例，B型124例，C型25例。其中开放性骨折36例，包括Gustilo Ⅰ型至ⅢA型，闭合性骨折201例。全部应用静力固定。结果：平均随访时间12个月(6～22个月)，闭合性骨折平均愈合时间15周(10～22周)，开放性骨折18周(13～36周)。12例延迟愈合，无深部感染、骨髓炎、畸形愈合、骨不连及断钉等并发症。全部患者术后邻近关节的功能均恢复正常。结论：扩髓交锁髓内钉是治疗股骨干骨折较理想的方法，骨折愈合率高，并发症较少。     

单臂外固定支架辅助闭合复位交锁髓内钉固定治疗股骨干粉碎性骨折

目的:介绍单臂外固定支架辅助闭合复位髓内钉内固定治疗股骨干骨折的手术方法和疗效。方法:自2008年6月至2012年10月,采用单臂外固定支架辅助闭合复位、交锁髓内钉固定治疗股骨干骨折24例,其中男19例,女5例;年龄20~68岁,平均45.6岁。车祸伤14例,坠落伤6例,重物砸伤4例,入院诊断均为股骨干骨折,手术在入院胫骨结节牵引1周左右进行。结果:所有患者获随访,时间6~24个月,平均16.2个月,X线示骨折愈合时间11~17周,平均13.8周,骨折全部愈合,无断钉或临近关节功能障碍。按照股骨干疗效评定标准,优23例,良1例。结论:单臂固定支架辅助闭合复位交锁髓内钉固定治疗股骨干骨折,具有创伤小、操作简单、复位有效、骨折愈合率高、并发症发生率低的优点。     

小切口闭合复位穿钉交锁髓内钉固定治疗胫骨粉碎骨折

目的探讨小切口闭合复位穿钉、交锁髓内钉固定治疗胫骨粉碎骨折的效果. 方法回顾性分析32例采用小切口闭合复位穿钉、交锁髓内钉固定治疗胫骨粉碎骨折的临床资料. 结果术后X线片复查均对线良好.28例B1、B2、B3型骨折骨愈合时间为6～8个月,取出髓内钉时间10～12个月;4例C2型骨折发生延迟愈合,骨愈合时间为24～36个月,取出髓内钉时间27～39个月.无骨折移位和不愈合,无皮肤坏死和骨外露. 结论小切口闭合复位穿钉、交锁髓内钉内固定的手术创伤小,有利于骨折愈合.     

经皮撬拔复位交锁钉内固定治疗胫骨干粉碎性骨折

目的：观察经皮撬拔复位交锁髓内钉内固定治疗胫骨干粉碎性骨折的临床应用及疗效。方法：本组胫骨干粉碎性骨折28例，其中男21例，女7例，全部为新鲜闭和骨折。骨折。骨折按AO分型：B1型6例、B2型8例、B3型6例；C1型4例、C2型3例、C3型1例。采用经皮小切口剥离器撬拔碎骨片使其复位闭和穿钉交锁髓内钉内固定。结果：经8-15个月(平均12．5个月)随访，骨折全部愈合，愈合时间平均4.8个月。按Klemm功能恢复分级标准：21例优、6例良，优良率96．4％。结论：经皮撬拔复位既能使骨折解剖复位或接近解剖复位，切口小、损伤小，局部血运破坏小，降低感染风险；有利于骨折愈合，同时降低了断钉、弯钉、骨折不愈合等交锁髓内钉的并发症，有较好的临床应用价值。     

三维定位交锁髓内钉固定股骨干骨折

目的：探讨使用三维远端瞄准器行交锁髓内钉内固定治疗股骨干骨折的临床疗效和术式选择。方法：对1998年6月-2002年10月使用交锁髓内钉静力固定治疗92例102股股骨干骨折的疗效进行回顾性分析。手术采用闭合、小切口或有限切开复位，用瞄准器锁定骨折远、近端。结果：92例均获得随访，随访平均时间14.2个月（6-58个月）。远期疗效按马元璋^[1]评定标准：优75例，良12例，可4例，差1例，优良率94.6%，平均骨临床愈合时间6.1个月，一期骨折愈合率达到93.1%，2例感染（感染率（2.8%)，2例髓内钉断裂。结论：交锁髓内钉治疗股骨干骨折应常规闭合复位、扩髓、静力固定，不强求解剖复位，三维远端瞄准器使远端锁钉达成三维定向，使静力固定方便确切。本组取得了满意疗效，认为是目前治疗股骨干骨折的首选方法。     

闭合复位带锁髓内钉固定治疗股骨干粉碎性骨折

目的评价应用闭合复位带锁髓内钉固定治疗股骨干粉碎性骨折的临床疗效。方法1999年8月-2005年4月，采用闭合复位顺行带锁髓内钉固定技术治疗股骨干粉碎性骨折70例。男54例，女16例；年龄17～58岁。骨折均位于股骨转子下2cm至股骨髁上5cm。按AO分型：B型17例，C型53例。受伤至手术时间为1～12d，平均5．8d。结果B型骨折患者手术时间为90-250min，C型骨折患者60～180min。70例失血量50-450ml，平均230ml。术中3例发生骨劈裂，1例C型骨折远端1枚锁钉锁入失误，7例肢体短缩1．0～1．5cm。68例获随访10～60个月，平均19个月。63例于术后3～10个月骨折愈合，5例于术后3～4个月行远端锁钉取出动力化后4～10个月骨折愈合。60例髋、膝关节功能活动优良，余8例髋或／和膝关节功能受限。结论闭合复位带锁髓内钉固定是治疗股骨干粉碎性骨折有效方法之一，具有损伤小、失血少、骨折愈合率高、功能恢复好的优点。     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Anterior Interosseous Nerve Palsy After Shoulder Arthroscopy Treated With Surgical Decompression: A Case Series and Systematic Review of the Literature

Background: Anterior interosseous nerve (AIN) palsy is a very uncommon cause of upper extremity pain and weakness that comprises less than 1% of all upper extremity nerve palsies. Rarely reported but also mentioned in the literature is AIN palsy after shoulder arthroscopy. Methods: A systematic review of the literature to date using PubMed was conducted to identify patients who suffered AIN palsy after shoulder arthroscopy procedures. Articles included met the following criteria: (1) published in English; (2) primary presentation of the data; (3) patients had undergone shoulder arthroscopy before developing symptoms of AIN palsy; and (4) diagnosis was confirmed with clinical symptoms of AIN palsy. Measured outcomes included patient demographics, specific shoulder procedure, anesthesia procedure, intra-operative patient positioning, intra-operative compressive dressing, intra-operative traction, surgical versus conservative treatment, abnormal findings during decompression procedure, proposed mechanism of injury, and follow-up. Results: The search yielded 6 articles, of which 4 (13 cases) met inclusion criteria. An additional 2 cases were included in this report totaling 15 cases. The average patient age was 49 years (range: 31-64) with 73% males. At average follow-up of 24 months, 67% of patients experienced complete resolution of symptoms—more than half of which underwent surgical decompression. Patients who failed to progress experienced weakness of the flexor digitorum profundus and flexor pollicis longus muscles. Conclusions: Proposed injury mechanisms for AIN palsy after shoulder arthroscopy range from mechanical trauma, compressive hematoma, and direct anesthetic neurotoxicity. Management should be directed by clinical symptoms, imaging, and patient factors with majority of patients expected to have excellent clinical outcomes.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Fluorescence in the Sclera,Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood’s light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood’s light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood’s light even two months after its cessation.     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Factors Associated With Reoperation After Silicone Proximal Interphalangeal Joint Arthroplasty

Background: Silicone proximal interphalangeal (PIP) joint arthroplasty has a high revision rate. It has been suggested that persistent ulnar deviation and joint instability influence the durability of PIP silicone arthroplasties. The goal of this study was to evaluate what factors are associated with reoperation after silicone PIP arthroplasty. Methods: We retrospectively evaluated all adult patients who underwent PIP silicone arthroplasty between 2002 and 2016 at one institutional system for inflammatory-, posttraumatic-, and primary degenerative arthritis. After manual chart review, we included 91 patients who underwent 114 arthroplasties. Fingers operated included 14 index, 41 middle, 38 ring, and 21 small fingers. Results: The overall reoperation rate was 14% (n = 16). Non-Caucasian race (P = .040), smoking (P = .022) and PIP silicone arthroplasty for post-traumatic osteoarthritis (P = .021) were associated with reoperation. The 1-, 5- and 10-year implant survival rates were 87%, 85%, and 85%, respectively. Conclusion: Caution should be exercised when considering PIP silicone arthroplasty of the index finger or in patients with post-traumatic osteoarthritis. It may be worthwhile addressing smoking behavior before pursuing silicone PIP arthroplasty.     

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系

目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。